Home › Islet Cell Adenoma › Illinois › Chicago
Islet Cell Adenoma clinical trials in Chicago, IL
4 studies for Islet Cell Adenoma are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
RecruitingPhase 3
- Investigative Site, Chicago
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
RecruitingPhase 2
- Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130), Chicago
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
RecruitingPhase 1
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
RecruitingPhase 2
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Islet Cell Adenoma trials in other cities
- Los Angeles, CA5 studies
- Rochester, MN5 studies
- St. Louis, MO5 studies
- Washington, DC4 studies
- Lexington, KY4 studies
- Portland, OR4 studies
- Phoenix, AZ4 studies
- Columbus, OH4 studies
- Salt Lake City, UT4 studies
- Cedar Rapids, IA3 studies
- Baltimore, MD3 studies
- Nashville, TN3 studies
Other studies in Chicago
- Non-Small Cell Lung Cancer61 studies
- Breast Cancer58 studies
- Cancer (all types)52 studies
- Metastatic Cancer45 studies
- Prostate Cancer45 studies
- Obesity42 studies
- Lung Cancer41 studies
- Ovarian Cancer36 studies
- Stroke34 studies
- Heart Failure32 studies
- Colorectal Cancer32 studies
- Overweight28 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.